GT
FRTX

Glenmede Trust’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Glenmede Trust’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Hold
0
– – – 3208
2019
Q1 		– Hold
0
– – – 3209
2013
Q3 		– Sell
-30
Closed -$296K – 2275
2013
Q2 		$296K Buy
+30
New +$332K ﹤0.01% 957

Other funds holding FRTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Glenmede Trust's FRTX Position: Q2 2019 in Review

Glenmede Trust held its Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) position steady in Q2 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3208.

Glenmede Trust first reported a position in FRTX in Q2 2013 and has held it in 1 quarter since. The position peaked at $296K in Q2 2013. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2019.

  • Glenmede Trust held 0 shares of Fresh Tracks Therapeutics, Inc. Common Stock worth $0 as of Q2 2019.
  • Glenmede Trust left its Fresh Tracks Therapeutics, Inc. Common Stock share count unchanged in Q2 2019.
  • Fresh Tracks Therapeutics, Inc. Common Stock made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2019, its #3208 holding.
  • Glenmede Trust first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 1 quarter since.
  • Glenmede Trust's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $296K in Q2 2013.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Glenmede Trust's 13F filing for Q2 2019, filed 13 Aug 2019.